Endocrine Tumor Board: Ten Years’ Experience of a Multidisciplinary Clinical Working Conference

Savitz, Alison; Fong, Bryan P.; Hochberg, Aaron; Rumore, Gregory J.; Cui, Chen; Yun, Juanita; Sadur, C N

doi:10.7812/tpp/19.140

Cited by 5 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, endocrine-specific tumor boards may not be as prevalent as those in other oncologic disciplines, and as a result, there is a paucity of data. 6 To our knowledge, there have been no studies examining patient experience and satisfaction with a multidisciplinary ETB. With the help of our survey, we hoped to gain some insight into how our tumor board impacts the patient experience outside of the typical outcome-based metrics such as treatment and survival.…”

Section: Discussionmentioning

confidence: 99%

“… 2 - 5 Additionally, tumor boards can ensure high-value care by preventing unnecessary tests or procedures. 6 …”

Section: Introductionmentioning

confidence: 99%

“…Endocrine tumor boards (ETBs) are potentially less common than tumor boards in other disciplines and represent a unique type of tumor board. 6 , 10 There is considerably less research surrounding ETBs. A multidisciplinary ETB was established at our NCI-designated comprehensive cancer center in 2016.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Multidisciplinary Endocrine Tumor Board: Assessment of the Patient Experience

Gorris,

Needham,

Finnegan

et al. 2024

Journal of Patient Experience

View full text Add to dashboard Cite

Research surrounding tumor boards has focused on patient outcomes and care coordination. Little is known about the patient experience with tumor boards. This survey examined aspects of the patient experience for patients presented at our multidisciplinary endocrine tumor board (ETB). A 15-item survey was distributed via the online patient portal to patients over the age of 18 whose case had been discussed at our ETB over an 18-month period. Descriptive statistics were reported, and a Fisher's exact test was used to examine relationships between variables. A total of 47 patients completed the survey (46%). A majority (72%) report their provider explained what the ETB is, and 77% report being informed their case would be discussed. Most patients were satisfied their case was being discussed (72%). A number of patients did report moderate or severe anxiety knowing their case was being discussed (15%). Sixty-four percent of patients report the ETB recommendations were clearly explained; however, satisfaction with the recommendations was slightly lower (53%). Despite the somewhat low satisfaction with the recommendations, 75% of patients felt more confident in their treatment plan knowing their case was discussed. Finally, if given the chance, 66% responded that they would have been interested in participating in their own ETB discussion. This study provides some insight into the patient experience surrounding tumor board discussions. Overall, patients are satisfied when their case is discussed at ETB. Patients can also experience anxiety about these discussions, and many patients desire to be present for their own discussions.

show abstract

Section: Discussionmentioning

confidence: 99%

“… 2 - 5 Additionally, tumor boards can ensure high-value care by preventing unnecessary tests or procedures. 6 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multidisciplinary Endocrine Tumor Board: Assessment of the Patient Experience

Gorris,

Needham,

Finnegan

et al. 2024

Journal of Patient Experience

View full text Add to dashboard Cite

show abstract

“…Optimal management of DTC requires a multidisciplinary team, and the decision to use RAI should be shared. 16 All members of the care team should be prepared to discuss the long-term impact of RAI, but nuclear medicine specialists, in particular, should be aware of this and other studies since they often lead the informed consent discussion before RAI administration. 17 Given the number and complexity of factors that play into decision making for therapy of DTC, aids can be helpful for patients to understand their condition and feel empowered in their decision making.…”

Section: The Takeawaymentioning

confidence: 99%

Radioactive Iodine: Recognizing the Need for Risk-Benefit Balance

McDonald

Lindeman

Bahl

2022

JCO

View full text Add to dashboard Cite

“…Endocrine tumor boards (ETBs), in contrast to classic oncologic boards include patients with both benign, beside malignant disease. The consensus opinions for diagnostic issues ranges from not pursuing any further testing to performing invasive procedures for more precise tumor characterization, including when to operate and how extensive a surgery should be performed [14]. A recent analysis showed that the suggested treatment was changed in 15 % of presentations, with additional imaging being the most frequent reason (43 %) [15].…”

Section: Introductionmentioning

confidence: 99%

Adrenal Surgery in the Era of Multidisciplinary Endocrine Tumor Boards

Hartmann

2022

Horm Metab Res

View full text Add to dashboard Cite

Work up of adrenal masses includes assessment of endocrine activity and malignancy risk. There is no indication for surgical removal of nonfunctional adrenal adenomas, according to the guidelines. In the present study, we aimed at evaluating the impact of a university endocrine tumor board on the quality of the indications for adrenal surgery at our institution. One hundred consecutive patients receiving primary adrenal surgery at the University Hospital of Cologne, Germany were included. Their demographics, clinic-pathologic characteristics, treatment and outcome were analyzed. In 55 (55%) cases, indication for surgery consisted in functional benign tumors, including Conn, Cushing adenomas and pheochromocytomas. Forty (40%) tumors were referred to surgery for malignancy suspicion and 5 (5%) myelolipomas were removed due to their size. Eighty-nine percent of surgeries were performed as minimally invasive procedures. Overall morbidity included two (2%) self-limiting pancreatic fistulas after left laparoscopic adrenalectomy for pheochromocytoma. All functional tumors were confirmed benign by final histology. Only 33 (82.5%) of 40 suspicious cases turned out to be malignant. Consequently, nonfunctional benign adenomas were “unnecessarily” removed in only 7 (7%) patients, with 6 (85.7%) of them having a history of extra-adrenal cancer and all of them fulfilling criteria for surgery, according to the international guidelines. In conclusion, the endocrine tumor board provided an excellent adherence to the guidelines with most surgeries being performed either for functional or malignant tumors. In nonfunctional tumors with history of extra adrenal cancer, CT guided biopsy might be considered for obviating surgery.

show abstract

Endocrine Tumor Board: Ten Years’ Experience of a Multidisciplinary Clinical Working Conference

Cited by 5 publications

References 11 publications

Multidisciplinary Endocrine Tumor Board: Assessment of the Patient Experience

Multidisciplinary Endocrine Tumor Board: Assessment of the Patient Experience

Radioactive Iodine: Recognizing the Need for Risk-Benefit Balance

Adrenal Surgery in the Era of Multidisciplinary Endocrine Tumor Boards

Contact Info

Product

Resources

About